Boehringer

1.9 Million Doses of NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): Donated by Boehringer Ingelheim Cares Foundation to Aid Shelter Dogs in Need

Retrieved on: 
Friday, March 15, 2024
Parasitism, Health, DSM-IV codes, Moxidectin, Coccidioides immitis, Boehringer Ingelheim, Tablet, Tick, Diarrhea, Dog, Lethargy, Boehringer, Breeding, Pet, Vomiting, Animal, Pharmaceutical industry

The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need.

Key Points: 
  • The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need.
  • The Foundation has donated 1.9 million doses of NexGard® PLUS chews, a delicious beef-flavored soft chew, designed to protect dogs from fleas and ticks, prevent heartworm disease, and treat and control roundworms and hookworms.
  • Over 6 million doses of NexGard® PLUS chews have been sold since its launch in 2023.
  • NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) are for use in dogs only.

Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment

Retrieved on: 
Thursday, February 22, 2024
Drug development, Patient, AML, Boehringer, Risk, Pharmaceutical industry

Notable is developing its lead drug asset volasertib with its proprietary PPMP for patients with relapsed/refractory acute myelogenous leukemia (r/r AML).

Key Points: 
  • Notable is developing its lead drug asset volasertib with its proprietary PPMP for patients with relapsed/refractory acute myelogenous leukemia (r/r AML).
  • “We in-licensed volasertib because of its robust clinical experience in Boehringer Ingelheim’s expansive Phases 1-3 program and our PPMP data that distinguished predicted volasertib-responders from predicted non-responders based on samples from patients with AML.
  • We therefore believe that PPMP will focus volasertib’s development on clinically responding patients, boost its clinical response rate and enhance patient outcomes,” continued Dr. Bock.
  • This analysis suggests that standardizing best supportive care and introducing body surface area-based dosing are likely to enhance patient responses and tolerability.

New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses

Retrieved on: 
Monday, February 19, 2024
Veterinarian, Doctor of Philosophy, Livestock, Artificial intelligence, Boehringer, Intelligence, DVM, Health, Animal, Farmer, Limp, Eye, Horse, Boehringer Ingelheim, Smartphone, Diagnosis, Movement, Human, Boehringer Ingelheim Animal Health, Gait, Partnership, Veterinary medicine

A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.

Key Points: 
  • A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.
  • This partnership delivers on the shared commitment of Boehringer and Sleip to deliver innovative solutions that help veterinary professionals continue to advance their profession and improve the care and wellbeing of horses.
  • Changes in gait and signs of lameness can be less pronounced at first and difficult to detect.
  • Through this collaboration, Boehringer will support the introduction of the pioneering Sleip app to the veterinary community, making this technology even more accessible.

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Retrieved on: 
Thursday, March 7, 2024
Pharmacy, Patient, Asthma, Boehringer Ingelheim, Boehringer, COPD, Policy, Health insurance

RIDGEFIELD, Conn., March 7, 2024 /PRNewswire/ -- Boehringer Ingelheim today announced it will cap out-of-pocket costs at $35 per month for eligible patientsi for all the company's inhaler products.

Key Points: 
  • RIDGEFIELD, Conn., March 7, 2024 /PRNewswire/ -- Boehringer Ingelheim today announced it will cap out-of-pocket costs at $35 per month for eligible patientsi for all the company's inhaler products.
  • Boehringer's new program will dramatically decrease costs at the pharmacy counter for the most vulnerable patients, including those who are uninsured or underinsured.
  • "Patients have counted on Boehringer Ingelheim for nearly 140 years to tackle challenges across diseases, including respiratory illnesses," said Jean-Michel Boers, President and CEO, Boehringer Ingelheim USA Corporation.
  • The company will continue to provide access to free products for eligible patients and comprehensive patient support programs as well.

The Scleroderma Research Foundation Appoints Dr. Gregory Gordon as Chief Medical Officer

Retrieved on: 
Thursday, January 25, 2024
Columbia Law School, Patient, JD, Therapy, State university system, Research, PTC Therapeutics, SAN, Scleroderma, Boehringer, Autoimmune disease, CONQUEST, Scleroderma Research Foundation, CMO, TiGenix, Harvard Vanguard Medical Associates, Doctor of Philosophy, SRF, Drug, Physician

SAN FRANCISCO, Jan. 25, 2024 /PRNewswire/ -- The Scleroderma Research Foundation (SRF)— the nation's largest non-profit funder of scleroderma research—announces the appointment of Gregory Gordon, MD, JD as its first Chief Medical Officer (CMO). As CMO, Dr. Gordon will provide both strategic management and operations oversight for the recently announced global clinical trial program CONQUEST, which will involve 130 medical centers in 22 countries. He will also liaise with CONQUEST's two pharmaceutical partners—Sanofi and Boehringer Ingelheim—as well as any other partners that opt to bring innovative therapies to the CONQUEST platform. Dr. Gordon's contributions are expected to add focus to the ongoing work of SRF—in particular regarding its efforts to bring new and innovative therapeutic alternatives to scleroderma patients and the scleroderma community worldwide.

Key Points: 
  • SAN FRANCISCO, Jan. 25, 2024 /PRNewswire/ -- The Scleroderma Research Foundation (SRF)— the nation's largest non-profit funder of scleroderma research—announces the appointment of Gregory Gordon, MD, JD as its first Chief Medical Officer (CMO).
  • "Dr. Gordon, with his impressive track record spanning over fifteen years in pivotal leadership roles in the biotechnology industry, brings a unique and vital perspective to the Scleroderma Research Foundation.
  • "With CONQUEST, the Scleroderma Research Foundation is deepening its commitment and support for research that addresses the high unmet needs of scleroderma patients.
  • Before attending medical school at the State University of New York at Stony Brook, Dr. Gordon earned a J.D.

Boehringer expands production site in Greece for new medicine

Retrieved on: 
Thursday, January 11, 2024
Patient, Professional, Corporate headquarters, Chronic liver disease, Boehringer, Scleroderma, Heart failure, Government, Mental health, Research and development, Pulmonary fibrosis, Chronic kidney disease, CRM, EUR, Boehringer Ingelheim, Workforce

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece.

Key Points: 
  • Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece.
  • Greek Prime Minister Kyriakos Mitsotakis attended the groundbreaking ceremony at the Koropi site today, alongside the Minister of State, the Minister of Health and the Minister of Development.
  • In 2020, the company announced multi-year investments to expand the site and its production capacity.
  • The Koropi plant is the only industrial facility of a multinational pharmaceutical company in Greece producing innovative medicines.

Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)

Retrieved on: 
Thursday, January 4, 2024
Dark, Science, Partnership, Protein, Neoplasm, Antigen, Boehringer Ingelheim, TCR, Vaccine, Lung cancer, Boehringer, Cancer, Genome, Patient, Exercise, Senior

Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®.

Key Points: 
  • Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®.
  • Based on the licensed antigens, Boehringer intends to develop novel off-the-shelf vaccines for the treatment of patients with NSCLC.
  • Under the collaboration, Enara Bio’s EDAPT platform is being used to discover and validate Dark Antigens in multiple solid tumor types.
  • During the antigen validation work package, Enara Bio demonstrated that the licensed antigens have several attractive characteristics as targets for immunotherapies.

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Retrieved on: 
Wednesday, January 3, 2024
RNA, RNA interference, Liver, Partnership, NASH, Boehringer Ingelheim, Cirrhosis, Hepatocyte, Small RNA, Boehringer, Research, Messenger, USD, DSM-IV codes, CRM, Liver failure, Liver cancer, Patient, Therapy, Senior, Pharmaceutical industry

INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

Key Points: 
  • INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
  • More than 440 million people worldwide are estimated to live with NASH, an inflammatory liver disease that is caused by accumulation of fat in the liver.
  • Over time, NASH causes scar tissue formation, which in many cases leads to liver cirrhosis and related serious complications, including liver failure or liver cancer.
  • We are very pleased about the opportunity to work with Boehringer Ingelheim to develop new solutions for people living with NASH."

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Retrieved on: 
Wednesday, January 3, 2024
RNA, RNA interference, Liver, Partnership, NASH, Boehringer Ingelheim, Cirrhosis, Hepatocyte, Small RNA, Boehringer, Research, Messenger, USD, DSM-IV codes, CRM, Liver failure, Liver cancer, Patient, Therapy, Senior, Pharmaceutical industry

INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

Key Points: 
  • INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
  • More than 440 million people worldwide are estimated to live with NASH, an inflammatory liver disease that is caused by accumulation of fat in the liver.
  • Over time, NASH causes scar tissue formation, which in many cases leads to liver cirrhosis and related serious complications, including liver failure or liver cancer.
  • We are very pleased about the opportunity to work with Boehringer Ingelheim to develop new solutions for people living with NASH."

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung

Retrieved on: 
Wednesday, November 29, 2023
Partnership, Food, Drug discovery, Boehringer Ingelheim, FDA, Lung, Disease, Boehringer, News, Orphan drug, NEC, Carcinoma, OBT, SCLC, Patient, ADC, DLL3, Fast Track, Pharmaceutical industry

BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for potential treatment of patients with LCNEC-Lung that is being developed by Boehringer Ingelheim.

Key Points: 
  • BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for potential treatment of patients with LCNEC-Lung that is being developed by Boehringer Ingelheim.
  • The discovery of BI 764532 (OBT620) was enabled through a successful partnership initiated in 2013, leveraging OBT’s proprietary OGAP® drug discovery platform for identification of the DLL3 antigen and Boehringer Ingelheim’s longstanding expertise in oncology and development of biotherapeutics.
  • BI 764532 was also granted Orphan Drug designation by the FDA for the treatment of SCLC, and is currently being investigated in a Phase 2 study, ‘DAREON™-5’ ( NCT05882058 ), in patients with relapsed/refractory extensive-stage SCLC and other relapsed/refractory NEC.
  • Christian Rohlff, Chief Executive Officer of OBT, commented: “We are delighted about the clinical development to help address unmet needs for people living with small cell lung cancer and other neuroendocrine carcinomas.